Nuclear NAD+-SIRT1 axis governs mtDNA heteroplasmy drift and determines aging trajectory

Hypothesis

Declining nuclear NAD+ levels with age reduce SIRT1 deacetylase activity, leading to hyperacetylated TFAM and POLG complexes that preferentially replicate deleterious mtDNA variants. Restoring NAD+ shifts the nuclear‑mitochondrial quality‑control balance toward wild‑type mtDNA, slowing heteroplasmy‑driven aging.

Mechanistic Reasoning

• NAD+ fuels SIRT1, which deacetylates TFAM and POLG, enhancing their affinity for canonical mtDNA promoters and improving replication fidelity.
• When NAD+ falls, acetylated TFAM binds mtDNA indiscriminately, allowing replication origins near mutant strands to fire more often, amplifying harmful heteroplasmy.
• This creates a feedback loop: increased mutant load raises ROS, further consuming NAD+ via PARP activation, worsening the defect.

Testable Predictions

1. Manipulation – Elevate nuclear NAD+ in Polγ mutator mice (e.g., with NR or NAMPT overexpression) and measure mtDNA heteroplasmy shift in liver, brain, and muscle.
2. Readout – Use duplex sequencing to quantify allele‑specific mtDNA fractions before and after intervention; predict a ≥20% reduction in pathogenic heteroplasmy after 8 weeks.
3. Phenotype – Expect median lifespan extension of ~15% and improved metabolic markers (VO2 max, insulin tolerance) correlating with heteroplasmy reduction.
4. Rescue test – SIRT1 knockout should abolish the NAD+‑mediated heteroplasmy shift, confirming epistatic placement.

Experimental Design

• Groups: (i) Wild‑type control, (ii) Polγ mutator vehicle, (iii) Polγ mutator + NAD+ booster, (iv) Polγ mutator + NAD+ booster + SIRT1 inhibitor.
• Timeline: Baseline at 3 months, treatment until 18 months, tissue harvest at 6‑month intervals.
• Assays: NAD+ metabolomics, SIRT1 activity assay, TFAM acetylation (immunoprecipitation‑Western), mtDNA copy number (qPCR), heteroplasmy (duplex sequencing), ROS (MitoSOX), frailty index.

Potential Outcomes & Interpretation

• If NAD+ boosting lowers pathogenic heteroplasmy and extends lifespan only when SIRT1 is present, the hypothesis gains strong support.
• If heteroplasmy remains unchanged despite NAD+ elevation, then nuclear‑driven mtDNA mutagenesis is likely downstream of other aging mechanisms, refuting the claim that the nuclear genome is a mere passenger.

Broader Implications

This framework unites nuclear metabolic state with mitochondrial genome dynamics, suggesting that effective anti‑aging strategies must concurrently target NAD+ metabolism and mtDNA quality control rather than treating either genome in isolation.